{
    "clinical_study": {
        "@rank": "105999", 
        "arm_group": [
            {
                "arm_group_label": "Bismuth subsalicylate", 
                "arm_group_type": "Experimental", 
                "description": "Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn whether bismuth subsalicylate can reduce use of\n      antibiotics among adults with diarrhea in Pakistan."
        }, 
        "brief_title": "Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan", 
        "condition": "Diarrhea", 
        "condition_browse": {
            "mesh_term": "Diarrhea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Persons aged 15 - 65 years old\n\n          -  Presenting with mild to moderate, non-bloody, acute diarrhea (\u22653 loose stools/day for\n             <3 days) to participating health care settings\n\n          -  For whom the study physicians recommend antimicrobial treatment\n\n        Exclusion Criteria:\n\n          -  Is pregnant\n\n          -  Requires hospitalization\n\n          -  Has signs or symptoms of septicemia\n\n          -  Has a primary complaint of another acute illness\n\n          -  Has a serious chronic illness\n\n          -  Has an allergy to aspirin\n\n          -  Has been exposed to antimicrobial or antidiarrheal medications within 72 hours of\n             enrollment\n\n          -  Previously enrolled in study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047162", 
            "org_study_id": "6469"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bismuth subsalicylate", 
                "intervention_name": "Bismuth subsalicylate", 
                "intervention_type": "Drug", 
                "other_name": "Pepto-Bismol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Bismuth", 
                "Bismuth subsalicylate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "diarrhea", 
            "gastroenteritis", 
            "antimicrobial drug resistance", 
            "antimicrobial agents", 
            "Pakistan", 
            "ambulatory care", 
            "bismuth"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "email": "agboat@hope-ngo.com", 
                "last_name": "Agboatwalla"
            }, 
            "facility": {
                "address": {
                    "city": "Karachi", 
                    "country": "Pakistan"
                }, 
                "name": "HOPE"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Pakistan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blind, Placebo-controlled Trial of the Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients in Pakistan", 
        "overall_contact": {
            "email": "agboat@hope-ngo.com", 
            "last_name": "Mubina Agboatwalla, MD", 
            "phone": "923 332 13 1960"
        }, 
        "overall_official": {
            "affiliation": "Centers for Disease Control and Prevention", 
            "last_name": "Anna Bowen, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "use of antimicrobial medications", 
            "safety_issue": "No", 
            "time_frame": "within 5 days of enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047162"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centers for Disease Control and Prevention", 
            "investigator_full_name": "Anna Bowen", 
            "investigator_title": "Medical Epidemiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient's perceived need for antibiotics", 
                "safety_issue": "No", 
                "time_frame": "Within 48 h of enrollment"
            }, 
            {
                "description": "Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness", 
                "measure": "additional care obtained for diarrhea", 
                "safety_issue": "No", 
                "time_frame": "within 48 h of enrollment"
            }, 
            {
                "description": "Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness", 
                "measure": "Additional care obtained for diarrheal illness", 
                "safety_issue": "No", 
                "time_frame": "within 5 days of enrollment"
            }, 
            {
                "description": "Time to first formed stool Number of stools during first 48 h of observation Duration of abdominal pain Duration of nausea Time to resolution of illness (any of the following symptoms: diarrhea, nausea, vomiting, abdominal pain) Severity of all symptoms of illness", 
                "measure": "Disease severity and duration", 
                "safety_issue": "No", 
                "time_frame": "within 5 days of enrollment"
            }, 
            {
                "description": "i.\tSatisfaction with resolution of symptoms ii.\tSatisfaction with esthetics of study medication iii.\tAdverse effects", 
                "measure": "Patient experience with the study drug", 
                "safety_issue": "No", 
                "time_frame": "within 5 days of enrollment"
            }
        ], 
        "source": "Centers for Disease Control and Prevention", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Procter and Gamble", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Health Oriented Preventive Education", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Centers for Disease Control and Prevention", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}